---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-021832"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-06-26T20:06:18+00:00"
generated_at: "2026-06-26T20:07:47.090721+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar reports ALXN1840 shows significant neurologic and global benefit in Phase 3 FoCus trial

## Summary
- ALXN1840 achieved significant neurologic improvement on UWDRS Part III (p=0.006) vs SOC (p=0.435) over 48 weeks.
- Global clinical improvement on CGI-I at Week 48 significantly greater with ALXN1840 vs SOC (p<0.001).
- Favorable safety profile: drug-related SAEs in 4.9% of patients, no treatment-related deaths.
- Results support planned NDA submission to FDA for ALXN1840 in mid-2026.

## SEC filing metadata
- accession: 0001437749-26-021832
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-06-26T20:06:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/0001437749-26-021832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/mnpr20260625_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-021832
- JSON: https://secwatch.observer/filing/0001437749-26-021832.json
- Plain text: https://secwatch.observer/filing/0001437749-26-021832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.